AZ Gains Japan Option To KHK Respiratory Antibody
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca is looking at extending its alliance with Japan's Kyowa Hakko Kirin for a respiratory disease antibody, picking up an option to commercialize the interleukin-targeting therapy in Japan in a move that will extend the UK-based firm’s respiratory interests in this major market.